The use of these drugs that target the hERG K+ channel (responsible for the delayed rectifier K+ current IKr) is constrained by the potential risk of inducing life-threatening ventricular arrhythmias through EADs (88). This evidence concerns the gene KCNH2 and Ventricular arrhythmia.